Calypso Biotech licenses CALY-001 best-in-class anti-MMP-9 antibody to EA Pharma

Geneva, March 29, 2017

Calypso Biotech licenses CALY-001 best-in-class anti-MMP-9 antibody to EA Pharma

Calypso Biotech SA announced today that it has entered a global licensing and collaboration agreement with EA Pharma Co., Ltd. to develop CALY-001, a best-in-class anti-MMP-9 fully human monoclonal antibody.

CALY-001 is a promising novel treatment for indications such as inflammatory bowel disease (IBD), potentially capable of preventing disease complications.

“This agreement highlights the strong potential for CALY-001, which possesses a unique mode of action through binding and inhibiting active MMP-9“ says Alain Vicari, CEO of Calypso Biotech. “By teaming with EA Pharma, a leader in gastrointestinal diseases with full value chain, we will fulfill our vision to bring new therapeutics to patients suffering from severe gastrointestinal diseases. Beyond IBD, CALY-001 represents a promising and advantageous therapeutic option for several oncology, inflammation and fibrosis indications”.

Under the agreement, Calypso Biotech will grant EA Pharma an exclusive and world-wide license for the development, manufacturing and marketing of CALY-001. Both companies will collaborate to develop CALY-001 for IBD. Calypso Biotech will receive an upfront, milestone and royalty payments from EA Pharma. Staatz Business Development & Strategy acted as transaction advisor to Calypso Biotech.

About MMP-9
Matrix metalloproteinase-9 (MMP-9) is an extracellular matrix-degrading enzyme. In IBD, MMP-9 is excessively expressed and activated within the inflamed gastrointestinal tissue. MMP-9 is also associated with other pathologies including cancer, chronic inflammation and fibrotic diseases. MMP-9 is mostly secreted as inactive pro-enzyme, which is activated when cleaved by other proteinases.

About CALY-001
CALY-001 is a novel, best-in-class fully human therapeutic antibody that uniquely binds to and neutralizes the active form of MMP-9. “This selective mode of action prevents in vivo antibody elimination through binding to the abundant pro-enzyme form of MMP-9, while preserving full enzymatic inhibition of activated and disease-relevant MMP-9” highlights Yolande Chvatchko, CSO of Calypso Biotech.

About Calypso Biotech SA
Calypso Biotech SA is a Swiss biotechnology company focused on the research and development of novel biologics in the gastrointestinal disease area. Calypso Biotech SA was established in 2013 as a spin-off from Merck and is funded by M Ventures,. For more information on Calypso Biotech SA, please see http://www.calypsobiotech.com/site/en/

About M Ventures
M Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. M Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base. For more information on M Ventures, please see http://merck-ventures.com

About EA Pharma Co., Ltd.
EA Pharma Co., Ltd. was inaugurated in April 2016 by integration of the Eisai Group’s gastrointestinal business unit with at least 60-year history and the Ajinomoto Group’s gastrointestinal business unit centered on amino acid. EA Pharma is a gastrointestinal specialty pharma, having a full value chain of research & development, production & logistics and sales & marketing. For more information on EA Pharma Co., Ltd., please see http://www.eapharma.co.jp/

Chief Executive Officer
Calypso Biotech SA

back to overview